Krystal Biotech, Inc. Krystal Biotech, Inc.

Krystal Biotech, Inc.

KRYS

Hisse Senetlerindeki Sıralama #2131
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Hisse Fiyatı
$322.07
Son senkronizasyon: 2026-10-21
Piyasa Değeri
$9.53B
Değişim (1 gün)
-1.03%
Değişim (1 yıl)
72.76%
Ülke
US
Ticaret Krystal Biotech, Inc. (KRYS)

Kategori

Healthcare
Krystal Biotech, Inc. (KRYS) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $326.06 - 2026-10-01

Gün sonu en düşük fiyat: $10.08 - 2017-09-01
Krystal Biotech, Inc. için hisse fiyatı geçmişi: 2017 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) 20.87%
2025 39.10%
2024 50.07%
2023 49.77%
2022 7.69%
2021 22.40%
2020 -4.80%
2019 169.14%
2018 129.54%
2017 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$527.18 23.62%
US
$251.29 835.90%
US
$137.44 -4.05%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH